(Press-News.org) Amsterdam, Netherlands – 26 Aug 2023: Cardiovascular disease (CVD) cost the EU an estimated €282 billion in 2021, according to late breaking research presented at ESC Congress 2023.1 Health and long-term care accounted for €155 billion (55%) of these costs, equalling 11% of EU health expenditure. The analysis was a collaborative effort by the European Society of Cardiology (ESC) and the University of Oxford, UK.
Study author Dr. Ramon Luengo-Fernandez of the University of Oxford said: “CVD had a significant impact on the EU27 economy, costing a total of €282 billion in 2021. That’s equivalent to 2% of Europe’s GDP and is significantly more than the entire EU budget2 itself, used to fund research, agriculture, infrastructure and energy across the Union.”
This was the most comprehensive and up-to-date analysis of the economic costs of CVD to society in the EU since 2006. It is the first study to use Europe-wide patient registries and surveys rather than relying on assumptions and, unlike previous reports, includes the costs of long-term social care. The current analysis provides estimates of the societal economic costs of CVD for the 27 members states of the EU in 2021, including 1) health and social care; 2) informal care; and 3) productivity losses. The breakdown includes:3
€130 billion for healthcare (46%)
€25 billion for social care (9%)
€79 billion for informal care (28%)
€15 billion in productivity losses due to illness/disability (5%)
€32 billion in productivity losses due to premature death (12%).
The total cost equated to €630 per EU citizen, ranging from €381 in Cyprus to €903 in Germany.4
CVD cost health and social care systems approximately €155 billion in 2021, accounting for 11% of total healthcare expenditure. There was wide variation between countries in the proportion of healthcare budgets spent on CVD, from 6% in Denmark to 19% in Hungary. Healthcare included primary care, emergency care, hospital care, outpatient care and medications, while social care included long-term institutionalised care, and care at home. The main contributor was hospital care, which cost €79 billion, representing 51% of CVD-related care costs. CVD medications accounted for €31 billion (20%) of care costs, followed by residential nursing care homes at €15 billion (9%).
Informal care costs included the work or leisure time, valued in monetary terms, that relatives and friends gave up to provide unpaid care. Relatives and friends provided 7.5 billion hours of unpaid care for patients with CVD, amounting to €79 billion across the EU.
Productivity losses included lost earnings due to illness/disability (early retirement/absenteeism) or premature death. In 2021, 256 million working-days were lost in the EU because of CVD illness/disability, at a cost of €15 billion. That same year, 1.7 million people died due to CVD across the EU, representing 1.3 million working-years lost, and generating productivity losses of €32 billion.
ESC Board member and study author Professor Victor Aboyans of Limoges University, France said: "This study underscores the urgent need to act collectively on the European scale to better combat the cardiovascular risk of European citizens, in particular through regulations for better cardiovascular prevention and investment in research. By choosing not to invest in cardiovascular disease we are simply deferring the cost. These data force us to ask the question: do we invest in cardiovascular health today or be forced to pay more at a later stage?”
Professor Panos Vardas, chief strategy officer of the European Heart Agency, the ESC’s office in Brussels, said: “Today’s presentation provides a clear understanding of the overall economic burden of cardiovascular disease across different EU countries, offering the opportunity to draw valuable conclusions that are useful for those responsible for designing healthcare plans. It is evident that there is significant fragmentation among EU countries in terms of cardiovascular disease healthcare expenditures. This necessitates a re-evaluation by the EU as a whole, and the 27 EU countries individually, to better address the outstanding needs and invest more effectively in supporting those suffering from cardiovascular disease.”
ENDS
Notes to editors
Authors: ESC Press Office
Mobile: +336 61 40 18 84
Email: press@escardio.org
The hashtag for ESC Congress 2023 is #ESCCongress.
Follow us on Twitter @ESCardioNews
Funding: This work was supported by an unrestricted grant from the European Society of Cardiology (ESC).
Disclosures: JL, AG and RLF report research grants from the ESC. ADT has stock in two start-up companies, receiving no income from these investments. AT has a consultancy agreement with ESC. APM reports payments from Astra Zeneca and Bayer for participation in study committees in areas outside the present work. PV reports consulting fees from Servier International, Hygeia Hospital Group and ESC. RH and ML report no disclosures.
References and notes
1Economic burden of CVD in the EU will be discussed during:
A press conference on Friday 25 August at 18:30 CEST.
The session Registries on cardiovascular risk and prevention on Saturday 26 August at 08:30 to 10:00 CEST in the Hub Rembrandt.
2EU budget: https://www.consilium.europa.eu/en/infographics/2023-eu-budget-main-areas/#:~:text=Infographic%20-%202023%20EU%20budget:%20Main,amount%20to%20%E2%82%AC168.6%20billion.Leal J, Luengo-
3Numbers total €281 (not €282) billion due to rounding. In particular, CVD cost the EU €281,537 million in 2021.
4Per EU country: CVD care costs as % of total health care expenditure and CVD costs per capita adjusted for price differentials.
About ESC Congress 2023
It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Amsterdam and online – from 25 to 28 August. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
END
Price tag on cardiovascular disease in Europe higher than entire EU budget
2023-08-28
ELSE PRESS RELEASES FROM THIS DATE:
NIH-funded study supports use of ECMO for critically ill patients with obesity
2023-08-28
NIH-funded study supports use of ECMO for critically ill patients with obesity
ECMO does not appear to complicate treatment for severe respiratory failure for adults with obesity
A National Institutes of Health-supported study suggests that adults with obesity may benefit from the use of extracorporeal membrane oxygenation (ECMO), an advanced form of breathing support, when in intensive care for respiratory failure. ECMO’s use was previously questioned for patients with obesity due to the belief that it may complicate ...
Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation
2023-08-28
About The Study: Muvalaplin was not associated with tolerability concerns and lowered lipoprotein(a) (Lp[a]) levels up to 65% following daily administration for 14 days in this first-in-human phase 1 study involving healthy participants. Lipoprotein(a) is associated with atherosclerotic disease and aortic stenosis. Longer and larger trials will be required to further evaluate safety, tolerability, and effect of muvalaplin on Lp(a) levels and cardiovascular outcomes.
Authors: Stephen J. Nicholls, M.B.B.S., Ph.D., of Monash University in Clayton, ...
Stevens researchers take aim at weather forecasters’ biggest blindspot
2023-08-28
Anyone who’s been caught in an unexpected downpour knows that weather forecasting is an imperfect science. Now, researchers at Stevens Institute of Technology are taking aim at one of meteorologists’ biggest blind spots: extremely short-term forecasts, or nowcasts, that predict what will happen in a given location over the next few minutes.
“This isn’t just about whether you should take your umbrella with you when you go on a walk,” said Temimi. “The forecasts that we’re missing – the ones that look ...
Projected outcomes of optimized statin and ezetimibe therapy in veterans with coronary artery disease
2023-08-28
About The Study: In this study of 111,000 U.S. military veterans with coronary artery disease, suboptimal lipid-lowering therapy was prevalent in the clinical setting. Optimization of statin therapy was projected to produce clinically relevant reductions in the risks of death and cardiovascular events. Despite a lesser lipid-lowering efficacy of ezetimibe, its widespread use on a population level in conjunction with optimized statin therapy may be associated with further meaningful reductions in cardiovascular risk.
Authors: Gregory G. Schwartz, M.D., Ph.D., of the Rocky Mountain Regional VA Medical Center in Aurora, Colorado, is the corresponding author.
To ...
COVID-19 virus is evolving rapidly in white-tailed deer
2023-08-28
COLUMBUS, Ohio – White-tailed deer across Ohio have been infected with the virus that causes COVID-19, new research has found – and the results also show that viral variants evolve about three times faster in deer than in humans.
Scientists collected 1,522 nasal swabs from free-ranging deer in 83 of the state’s 88 counties between November 2021 and March 2022. More than 10% of the samples were positive for the SARS-CoV-2 virus, and at least one positive case was found in 59% of the counties in which testing took place.
Genomic analysis showed that at least 30 infections in deer had been introduced by humans – ...
Are cannabis products safe and effective for reducing symptoms in children with cancer?
2023-08-28
A recent analysis of all relevant published studies reveals a lack of evidence to determine the dosing, safety, and efficacy of medical marijuana or cannabis-containing products for managing symptoms experienced by children with cancer. The analysis is published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
Although treatments for childhood cancer have improved significantly, even leading to cures for many patients, many children still suffer from symptoms such as pain, anxiety, and weight loss related to cancer and its treatment. Over the last decade, cannabis ...
First defence against devastating ToCSV tomato virus explored
2023-08-28
How tomato plants defend themselves against a devastating ‘young’ Southern African virus has now been investigated at a molecular genetics level for the first time by researchers at the University of Johannesburg (UJ).
The Ty-1 gene is known to confer resistance to the well-known tomato yellow leaf curl virus (TYLCV). UJ researchers investigated what happens when tomato plants that harbour the Ty-1 gene are infected with the relatively unknown tomato curly stunt virus (ToCSV). They found a link between tolerance to ToCSV, a plant defence called viral DNA methylation, and Ty-1 gene activity.
The research is published ...
Sleep can be most restful for older adults when nighttime temperature range is between 68 to 77 °F, study finds
2023-08-28
New research finds that sleep can be most efficient and restful for older adults when nighttime bedroom ambient temperature ranges between 68 to 77 °F.
The authors observed an overall trend: a 5-10 % drop in sleep efficiency as the nighttime ambient temperature increases from 77°F to 86°F. Importantly, this research also reveals substantial between-individual differences in optimal bedroom temperature.
“These results highlight the potential to enhance sleep quality in older adults by optimizing home thermal environments and emphasizing the importance ...
New study reveals anti-cancer properties in Kencur ginger
2023-08-28
You may know it as an aromatic spice to add flavor to your dishes or as a soothing herbal remedy to use for upset stomachs, but researchers from Osaka Metropolitan University have uncovered promising findings that Kencur, a tropical plant in the ginger family native to Southeast Asia, possesses anti-cancer effects.
Led by Associate Professor Akiko Kojima of the Graduate School of Human Life and Ecology, the researchers demonstrated that Kencur extract and its main active component, ethyl p-methoxycinnamate (EMC), significantly suppressed cancer cell growth at the cellular and animal levels.
While previous studies on EMC indicated its anti-cancer potential by decreasing the expression ...
New type of visible-light responsive photocatalyst is efficient, stable and very economical
2023-08-28
A new type of versatile economical photocatalyst that harnesses the visible portion of the sunlight spectrum has been developed by researchers from the University of Johannesburg. It is simple to manufacture.
Currently, economical photocatalysts only ‘use’ the UV spectrum of sunlight.
The new photocatalyst harnesses about a third of the visible light spectrum.
The extremely stable, powder-form three-component photocatalyst is built from graphitic carbon (89% of mass), a modified calixarene (10%) and a niobium-containing MXene (1%).
Researchers at the University of Johannesburg have developed a new type of photocatalyst that harnesses the visible ...